ReviewThe Lancet regional health. Europe2024
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
Review in The Lancet regional health. Europe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.The oncologist · 2025Pooled it
- Guideline
- Reporting of somatic variants in clinical cancer care: recommendations of the Swiss Society of Molecular Pathology.Virchows Archiv : an international journal of pathology · 2024Guideline
- Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review.Future oncology (London, England) · 2024Pooled it
- Multi-Omics and Machine Learning Identify Immune-Linked Gene Signatures for LUAD Stratification.Genes · 2026Article
- Review
- Transforming routine solid tumor profiling with automated next-generation sequencing: experience from a reference general hospital.Virchows Archiv : an international journal of pathology · 2026Article
- Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.Translational oncology · 2026Article
- Cost-effectiveness analysis of molecular reflex testing-based targeted therapy in non-small cell lung cancer from a German healthcare payer perspective using a decision tree model.Cost effectiveness and resource allocation : C/E · 2026Article
- Clinical significance of serum levels of 14-3-3β protein in patients with non-small cell lung cancer.Scientific reports · 2026Article
- Large language model-based approach for low-cost, rapid and accurate automated extraction of predictive biomarker testing results from Dutch pathology reports.Virchows Archiv : an international journal of pathology · 2026Article
- Clinicopathological characteristics of patients with inoperable non-small cell lung cancer harboring circulating NRF2 pathway mutations.The Journal of pathology · 2026Article
- Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Cancer medicine · 2026Article
- Observational
- Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma.Frontiers in oncology · 2026Article
- Body mass index and fasting insulin predict survival and EGFR-TKI benefit in Stage IV lung adenocarcinoma.Frontiers in oncology · 2026Article
- Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR-TKI benefit in stage IV lung adenocarcinoma.Frontiers in oncology · 2026Article
- Whole genome characterization of patient-derived lung cancer organoids.Translational lung cancer research · 2025Article
- Article
- Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer.Future oncology (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 14 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.